02Jun
02Jun
7 Standout Sustainability Innovations We Covered This Spring
From planetary warming to plastic waste, it's easy to get bogged down in all the bad news out there. But let's not forget that innovators around the world are on the case, doing largely unsung work on a daily basis to scale solutions with the potential to address these challenges head on. A water-based alternative to PFAS - The group of chemicals known as PFAS are ubiquitous in modern life. Young entrepreneur David Zamarin started working to develop PFAS alternatives...
01Jun
Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program
Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $294,000 Small Business Technology Transfer Research (STTR) grant to: (i) demonstrate that a formulation of N-acylethanolamine (AEA or anandamide) loaded into Zylö’s novel Z-pod delivery system is efficacious (and well tolerated) in a new mouse model of cutaneous lupus developed at Yale University, and (ii) conduct preliminary stability studies to prepare for an eventual investigational new drug (IND) application to the FDA. Read more >>
01Jun
Wasabi Fenway Park Bowl returning in 2023
Fenway Park is going bowling again. The home of the Boston Red Sox will play host to the Wasabi Fenway Park Bowl for the second straight year, it was announced Wednesday. The game will take place on December 28, 2023 at 11 a.m., and will once again feature teams from the American Athletic Conference (AAC) and Atlantic Coast Conference (ACC). Read more >>
23May
RevBio Receives ISO 13485 Certification for its Quality Management System
RevBio, Inc., announced that it has received ISO 13485 certification for its quality management system. Receiving ISO 13485 certification indicates that a company has developed robust policies and procedures for the development and manufacture of regulated medical products. “Having built my career in quality management over the last 35 years, I have been through over 25 ISO 13485 audits and many FDA audits,” said Gary Bunnewith, RevBio’s Director of Quality. “None have been as exciting as developing a quality management...
23May
Nixing PFAS is a Real Possibility: Here’s One Company That’s Doing It
Per- and polyfluorinated substances (PFAS) have been getting a lot of negative publicity. And with good reason. Classified as “forever chemicals,” they’ve been found in food, water, soil, animals and even our blood. Although the extent of their effects is not fully understood, they are known to negatively impact human health in a variety of ways. But while many are calling for an overall ban on the chemicals, pushback from the industry seeks to simply switch out the PFAS we...
20May
PNC Bank Expands Financial Wellness Offerings With PNC Student Debt Solution, Powered by Candidly™
PNC Bank, N.A. today announced an expansion of its financial wellness offerings for clients through the introduction of PNC Student Debt Solution, powered by Candidly™, a student debt and savings optimization platform. Read more >>
13May
CytoAgents reaches FDA milestone and closes on $7 million funding round led by PCG Capital
A Pittsburgh-based biotech startup announced it reached the next milestone in its pursuit of full U.S. Food and Drug Administration (FDA) approval for its drug that looks to aid cancer patients undergoing immunotherapy treatment. This new clearance for CytoAgents Inc., which employs four people full-time, comes just days after the startup closed on a $7 million Series A2 equity-based funding round, which Pittsburgh-based PCG Capital led with support from BlueTree Allied Angels and a syndicate of local oncologists. It brings...
12May
CytoAgents Announces FDA Acceptance of IND Application for CTO1681 to Treat Cytokine Release Syndrome in Oncology
CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA). This clearance enables the initiation of a U.S. Phase 1b/2a clinical trial under its Investigational New Drug (IND) application for the therapeutic, CTO1681, to treat CRS in lymphoma patients receiving CAR T-Cell Therapy. This is an area of great unmet medical need as the majority...
12May